In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: ArcBest's current price exceeds its PERT-weighted fair value by 27.4%, indicating potential overvaluation supported by low profitability and liquidity scores. Monte Carlo analysis shows all downside scenarios below current price, reflecting high risk with a broad valuation range and mixed analyst targets. Strong growth contrasts with operational inefficiencies, increasing valuation uncertainty.